Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo

Wang, Yihua; Liu, Shuang; Guo, Zhiyong; Zhou, Cuiqi; Zhu, Hongxia; Zhou, Xiaobo; Quan, Lanping; Bai, Jinfeng; Xu, Nuo

doi:10.1186/bcr975

Cited by 136 publications

(52 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, Sp1 can directly interact with the c-Jun transcription factor to modulate the up-regulation of vimentin, a protein commonly found misregulated in metastatic tumors (40). Sp1 itself has been shown to be a useful molecular marker is gastric cancer and Sp1 expression has been shown to be closely associated with patient survival rate (16,41).…”

mentioning

confidence: 99%

Regulation of KiSS-1 Metastasis Suppressor Gene Expression in Breast Cancer Cells by Direct Interaction of Transcription Factors Activator Protein-2α and Specificity Protein-1

Mitchell

Abdelrahim

Weng

et al. 2006

Journal of Biological Chemistry

View full text Add to dashboard Cite

mentioning

confidence: 99%

Regulation of KiSS-1 Metastasis Suppressor Gene Expression in Breast Cancer Cells by Direct Interaction of Transcription Factors Activator Protein-2α and Specificity Protein-1

Mitchell

Abdelrahim

Weng

et al. 2006

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Another study showed that siRNA could be used in vitro to inhibit West Nile virus replication. It was also found that siRNAs could provide some protection from lethal West Nile virus infection in mice [67]. Recently, potent siRNA inhibitors of SARS coronavirus in vitro have been shown to highly effective in suppressing SARS-like symptoms and phenotypes in an in vivo rhesus macaque SARS model using clinical viable delivery methods [69].…”

Section: Therapeutic Applicationsmentioning

confidence: 98%

“…In one study, researchers found that the growth of the human breast cancer derived cell line MCF-7 could be inhibited by siRNA targeted to the c-myc gene in vitro and in vivo [67]. In another study it was found that siRNA could be used to decrease the expression of IL-10 on both the mRNA and protein levels in a dose and time dependant manner [58].…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

“…Studies have been conducted to examine the effectiveness of using RNAi to treat viral diseases such as HIV infection [63,64], hepatitis [62,66,68], and West Nile virus [67] and poliovirus [65] infections. One study recognized the production of miRNAs specific to the HIV gene nef in infected cells [64].…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

“…These studies either aim to assess the function of a target gene [48,49], to identify potential therapeutic targets [50][51][52] or to test the viability of RNAi in the treatment of various diseases. So far, RNAi has been investigated for its effectiveness in treating cancer [53][54][55][56][57][58][59], neurological diseases [60,61] and viral diseases [62][63][64][65][66][67][68].…”

Section: Mechanism Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

Destroying RNA as a Therapeutic Approach

Tafech¹,

Bassett²,

Sparanese³

et al. 2006

CMC

View full text Add to dashboard Cite

The ability to target RNA, mRNA and viral RNA in particular, for degradation is a powerful approach in molecular biology and pharmacology. Such approaches can be used in the study of gene function as in functional genomics, in the identification of disease-associated genes, and for the treatment of human diseases. This review provides a comprehensive up-to-date look at all the current available technologies used for the destruction of RNA, with a focus on their therapeutic potential. This includes approaches that utilize the activity of protein ribonucleases such as antisense oligonucleotide, small interfering RNA, RNase P-associated external guide sequence, onconase and bovine seminal RNase. Sequence-specific approaches that do not utilize activity of protein ribonucleases, such as ribozyme and DNazyme, are also reviewed and discussed. This review should provide a useful starting framework for researchers interested in using the RNA-destruction methodologies on the bench and in the clinic, and serves as a stimulus for further development of novel and more potent RNA degradation technologies. This is particularly critical, given the anticipation of discoveries of new cellular RNA degradation machineries and human diseases that are associated with dysfunctional RNA molecules.

show abstract

CRISPR/Cas9 screen for genome‐wide interrogation of essential MYC‐bound E‐boxes in cancer cells

et al. 2023

View full text Add to dashboard Cite

The transcription factor MYC is a proto‐oncogene with a well‐documented essential role in the pathogenesis and maintenance of several types of cancer. MYC binds to specific E‐box sequences in the genome to regulate gene expression in a cell‐type‐ and developmental‐stage‐specific manner. To date, a combined analysis of essential MYC‐bound E‐boxes and their downstream target genes important for growth of different types of cancer is missing. In this study, we designed a CRISPR/Cas9 library to destroy E‐box sequences in a genome‐wide fashion. In parallel, we used the Brunello library to knock out protein‐coding genes. We performed high‐throughput screens with these libraries in four MYC‐dependent cancer cell lines—K562, ST486, HepG2, and MCF7—which revealed several essential E‐boxes and genes. Among them, we pinpointed crucial common and cell‐type‐specific MYC‐regulated genes involved in pathways associated with cancer development. Extensive validation of our approach confirmed that E‐box disruption affects MYC binding, target‐gene expression, and cell proliferation in vitro as well as tumor growth in vivo. Our unique, well‐validated tool opens new possibilities to gain novel insights into MYC‐dependent vulnerabilities in cancer cells.

show abstract

Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo

Cited by 136 publications

References 37 publications

Regulation of KiSS-1 Metastasis Suppressor Gene Expression in Breast Cancer Cells by Direct Interaction of Transcription Factors Activator Protein-2α and Specificity Protein-1

Regulation of KiSS-1 Metastasis Suppressor Gene Expression in Breast Cancer Cells by Direct Interaction of Transcription Factors Activator Protein-2α and Specificity Protein-1

Destroying RNA as a Therapeutic Approach

CRISPR/Cas9 screen for genome‐wide interrogation of essential MYC‐bound E‐boxes in cancer cells

Contact Info

Product

Resources

About